• In early February 2026, multiple law firms filed securities fraud class action lawsuits against uniQure N.V., alleging that the company misled investors about U.S. FDA alignment, pivotal study design, and the likelihood of accelerated approval for its Huntington’s disease gene therapy candidate, AMT-130, during late 2025.
• At the same time, uniQure reported new Phase I/IIa data on its Fabry disease program AMT-191, underscoring a broader pipeline but also highlighting clinical and safety uncertainties that now sit alongside material legal and regulatory questions around its lead Huntington’s program.
• We’ll now examine how the AMT-130-related securities lawsuits and FDA concerns may reshape uniQure’s investment narrative centered on regulatory milestones.

Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

uniQure Investment Narrative Recap

To own uniQure right now, you have to believe that gene therapies like AMT-130 and AMT-191 can eventually justify years of heavy investment and clinical risk. In the near term, the key catalyst had been an AMT-130 BLA path with the FDA, but the securities fraud lawsuits and earlier FDA pushback now make regulatory timing and trial requirements the central risk to the story.

The February 2026 class action filings focus squarely on AMT-130’s FDA alignment, directly challenging what had been framed as a near term accelerated approval opportunity. In contrast, the updated AMT-191 Fabry data at WORLDSymposium, with elevated a-Gal A activity and a manageable safety profile in 11 patients, points to pipeline breadth but does not offset the heightened uncertainty around AMT-130’s regulatory route.

Yet investors should also weigh how the FDA’s shift on AMT-130’s external control data could force longer, costlier trials that...

uniQure's narrative projects $306.4 million revenue and $32.3 million earnings by 2028.

Uncover how uniQure's forecasts yield a $54.42 fair value, a 150% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already cautious, assuming revenue would only reach about US$41.0 million by 2028 and still not expecting profitability, so this new FDA and litigation overhang may push their already more pessimistic views on regulatory risk and trial length even further from the more optimistic consensus you often see.

Explore 5 other fair value estimates on uniQure - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your uniQure research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free uniQure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate uniQure's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Find 56 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.